UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 509

Sortiert nach

Case Definition and Phenotype Standardization in Drug-Induced Liver Injury

Clinical pharmacology and therapeutics, 2011-06, Vol.89 (6), p.806-815

2011

Link zum Volltext

Verfügbarkeit prüfen

The negative impact of HBV/HCV coinfection on cirrhosis and its consequences

Alimentary pharmacology & therapeutics, 2017-12, Vol.46 (11-12), p.1054-1060

2017

Link zum Volltext

Verfügbarkeit prüfen

Lomitapide hepatic safety: A long-term retrospective analysis in patients with homozygous familial hypercholesterolaemia

Atherosclerosis plus, 2023-12, Vol.54, p.S2-S3

2023

Link zum Volltext

Verfügbarkeit prüfen

Tacrolimus and the Risk of Solid Cancers After Liver Transplant: A Dose Effect Relationship

American journal of transplantation, 2015-03, Vol.15 (3), p.678-686

2015

Link zum Volltext

Verfügbarkeit prüfen

154 PREVALENCE OF ADENOMATOUS COLON POLYPS AFTER LIVER TRANSPLANTATION (LT): THE LEVEL OF IMMUNOSUPPRESSION MAKES THE DIFFERENCE

Journal of hepatology, 2013-04, Vol.58, p.S69-S69

2013

Link zum Volltext

Verfügbarkeit prüfen

1108 SELECTION OF HCV GENOTYPE 1 PATIENTS FOR DUAL THERAPY WITH PEGINTERFERON ALFA-2A/RIBAVIRIN WITH A HIGH PROBABILITY OF SUSTAINED VIROLOGIC RESPONSE ACCORDING TO BASELINE CHARACTERISTICS ALONE

Journal of hepatology, 2012-04, Vol.56, p.S436-S436

2012

Link zum Volltext

Verfügbarkeit prüfen

Hépatotoxicité des immunosuppresseurs. Conduite diagnostique

Gastroentérologie clinique et biologique, 2008-05, Vol.32 (5), p.S194-S204

Larrey, D.

2008

Link zum Volltext

Verfügbarkeit prüfen

Foie, médicaments et agents chimiques

Gastroentérologie clinique et biologique, 2009-12, Vol.33 (12), p.1136-1146

Larrey, D.

2009

Link zum Volltext

Verfügbarkeit prüfen

HCV eradication reduces the occurrence of major adverse cardiovascular events in hepatitis C cirrhotic patients: data from the prospective ANRS CO12 CirVir cohort

Journal of hepatology, 2017, Vol.66 (1), p.S20-S21

2017

Link zum Volltext

Verfügbarkeit prüfen

Identifying residual risk of hepatocellular carcinoma following hepatitis C virus eradication in compensated cirrhosis: decision-tree and random forest models developed in the French multicenter prospective ANRS CO12 CirVir cohort

Journal of hepatology, 2017, Vol.66 (1), p.S21-S22

2017

Link zum Volltext

Verfügbarkeit prüfen

Hepatotoxicity of immunosuppressants. Diagnostic approach

Gastroentérologie clinique et biologique, 2008-05, Vol.32 (5 Pt 2), p.S194

Larrey, D

2008

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness and cost-effectiveness of antiviral treatment initiation in hepatitis C related decompensated cirrhosis in France

Journal of hepatology, 2017, Vol.66 (1), p.S414-S415

2017

Link zum Volltext

Verfügbarkeit prüfen

Facteurs socio-comportementaux associés à la mortalité de cause hépatique et non hépatique chez les patients atteints d’hépatite C chronique (cohorte ANRS CO22 HEPATHER)

Revue d'épidémiologie et de santé publique, 2021-06, Vol.69, p.S32-S32

2021

Link zum Volltext

Verfügbarkeit prüfen

62 ACTIVITY OF DANOPREVIR PLUS LOW-DOSE RITONAVIR (DNV/R) IN COMBINATION WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN (PEGIFNa-2A/RBV) IN PREVIOUS NULL RESPONDERS

Journal of hepatology, 2011-03, Vol.54, p.S28-S28

2011

Link zum Volltext

Verfügbarkeit prüfen

Clinical and Social Psychological Profiles of Patients with Chronic Hepatitis C Treated with IFN-Free Regimens in France

Journal of hepatology, 2016, Vol.64 (2), p.S468-S469

2016

Link zum Volltext

Verfügbarkeit prüfen

Epidemiology and Individual Susceptibility to Adverse Drug Reactions Affecting the Liver

Seminars in liver disease, 2002, Vol.22 (2), p.145-156

Larrey, Dominique

2002

Link zum Volltext

Verfügbarkeit prüfen

Concomitant or Consecutive Infection with Coxiella burnetii and Tickborne Diseases

Clinical infectious diseases, 2005-01, Vol.40 (1), p.82-88

2005

Link zum Volltext

Verfügbarkeit prüfen

Drug-induced acute liver failure

European journal of gastroenterology & hepatology, 2005-02, Vol.17 (2), p.141-143

2005

Link zum Volltext

Verfügbarkeit prüfen

Viral Suppression is Not a risk Factor for CKD in Viral Cirrhosis (ANRS CO12 CirVir Prospective Cohort)

Journal of hepatology, 2016, Vol.64 (2), p.S256-S256

2016

Link zum Volltext

Verfügbarkeit prüfen

New Recommendations of Baveno Vi Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort)

Journal of hepatology, 2016, Vol.64 (2), p.S178-S178

2016

Link zum Volltext

Verfügbarkeit prüfen

The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort)

Journal of hepatology, 2016, Vol.64 (2), p.S655-S656

2016

Link zum Volltext

Verfügbarkeit prüfen

Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort)

Journal of hepatology, 2016, Vol.64 (2), p.S273-S273

2016

Link zum Volltext

Verfügbarkeit prüfen

P0808 : Improvement in liver function and non-invasive estimates of liver fibrosis 48 weeks after treatment with ombitasvir/paritaprevir/R, dasabuvir and ribavirin in HCV genotype 1 patients with cirrhosis

Journal of hepatology, 2015-04, Vol.62, p.S637-S638

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 509

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(389)
Mit Volltextzugriff
(368)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(254)
Science & Technology
(188)
Life Sciences & Biomedicine
(181)
Male
(162)
Female
(154)
Biological And Medical Sciences
(124)
Middle Aged
(124)
Medical Sciences
(122)
Adult
(115)
Gastroenterology & Hepatology
(89)
Pharmacology. Drug Treatments
(82)
Aged
(78)
Gastroenterology And Hepatology
(69)
Chemical And Drug Induced Liver Injury - Etiology
(55)
Drug Toxicity And Drugs Side Effects Treatment
(49)
Pharmacology & Pharmacy
(45)
Toxicity: Digestive System
(43)
Animals
(40)
Life Sciences
(39)
Acute Disease
(30)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Hepatology
(126)
Gastroentérologie Clinique Et Biologique
(76)
Biochemical Pharmacology
(19)
Hepatology
(18)
La Presse Médicale
(15)
Gastroenterology
(14)
Gut
(14)
The Journal Of Pharmacology And Experimental Therapeutics
(11)
Military Surgeon
(10)
Therapie
(6)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Case Definition and Phenotype Standardization in Drug-Induced Liver Injury

The negative impact of HBV/HCV coinfection on cirrhosis and its consequences

Lomitapide hepatic safety: A long-term retrospective analysis in patients with homozygous familial hypercholesterolaemia

Tacrolimus and the Risk of Solid Cancers After Liver Transplant: A Dose Effect Relationship

154 PREVALENCE OF ADENOMATOUS COLON POLYPS AFTER LIVER TRANSPLANTATION (LT): THE LEVEL OF IMMUNOSUPPRESSION MAKES THE DIFFERENCE

1108 SELECTION OF HCV GENOTYPE 1 PATIENTS FOR DUAL THERAPY WITH PEGINTERFERON ALFA-2A/RIBAVIRIN WITH A HIGH PROBABILITY OF SUSTAINED VIROLOGIC RESPONSE ACCORDING TO BASELINE CHARACTERISTICS ALONE

Hépatotoxicité des immunosuppresseurs. Conduite diagnostique

Foie, médicaments et agents chimiques

HCV eradication reduces the occurrence of major adverse cardiovascular events in hepatitis C cirrhotic patients: data from the prospective ANRS CO12 CirVir cohort

Identifying residual risk of hepatocellular carcinoma following hepatitis C virus eradication in compensated cirrhosis: decision-tree and random forest models developed in the French multicenter prospective ANRS CO12 CirVir cohort

Hepatotoxicity of immunosuppressants. Diagnostic approach

Effectiveness and cost-effectiveness of antiviral treatment initiation in hepatitis C related decompensated cirrhosis in France

Facteurs socio-comportementaux associés à la mortalité de cause hépatique et non hépatique chez les patients atteints d’hépatite C chronique (cohorte ANRS CO22 HEPATHER)

62 ACTIVITY OF DANOPREVIR PLUS LOW-DOSE RITONAVIR (DNV/R) IN COMBINATION WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN (PEGIFNa-2A/RBV) IN PREVIOUS NULL RESPONDERS

Clinical and Social Psychological Profiles of Patients with Chronic Hepatitis C Treated with IFN-Free Regimens in France

Epidemiology and Individual Susceptibility to Adverse Drug Reactions Affecting the Liver

Concomitant or Consecutive Infection with Coxiella burnetii and Tickborne Diseases

Drug-induced acute liver failure

Viral Suppression is Not a risk Factor for CKD in Viral Cirrhosis (ANRS CO12 CirVir Prospective Cohort)

New Recommendations of Baveno Vi Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort)

The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort)

A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)

Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort)

Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort)

P0808 : Improvement in liver function and non-invasive estimates of liver fibrosis 48 weeks after treatment with ombitasvir/paritaprevir/R, dasabuvir and ribavirin in HCV genotype 1 patients with cirrhosis

Suchergebnisse filtern